These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29293113)

  • 21. Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis.
    Lian F; Zhou J; Wang Y; Chen D; Xu H; Liang L
    Clin Exp Rheumatol; 2018; 36(5):884-890. PubMed ID: 29652659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
    Rheumatology (Oxford); 2008 Jun; 47(6):872-6. PubMed ID: 18400836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
    Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
    Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
    Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
    Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etanercept is effective as monotherapy or in combination with methotrexate in rheumatoid arthritis: subanalysis of an observational study.
    Gaubitz M; Göttl KH; Behmer O; Lippe R; Meng T; Löschmann PA
    Clin Rheumatol; 2017 Sep; 36(9):1989-1996. PubMed ID: 28756532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
    Lubrano E; Parsons WJ; Perrotta FM
    J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
    Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
    Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.
    Bonifati C; De Felice C; Lora V; Morrone A; Graceffa D
    J Dermatolog Treat; 2020 Nov; 31(7):687-691. PubMed ID: 30985223
    [No Abstract]   [Full Text] [Related]  

  • 32. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Etanercept in psoriatic arthritis.
    Spadaro A; Lubrano E; Ferrara N; Scarpa R
    J Rheumatol Suppl; 2012 Jul; 89():74-6. PubMed ID: 22751599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
    Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Tsuji W
    Arthritis Rheum; 2004 Jul; 50(7):2264-72. PubMed ID: 15248226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effects of 5-year Etanercept Therapy on Cardiovascular Risk Factors in Patients with Psoriatic Arthritis.
    Agca R; Heslinga M; Kneepkens EL; van Dongen C; Nurmohamed MT
    J Rheumatol; 2017 Sep; 44(9):1362-1368. PubMed ID: 28572461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
    Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Dunn M; Tsuji W
    J Rheumatol; 2006 Apr; 33(4):712-21. PubMed ID: 16463435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.
    FitzGerald O; Helliwell P; Mease P; Mumtaz A; Coates L; Pedersen R; Nab H; Molta C
    Ann Rheum Dis; 2012 Mar; 71(3):358-62. PubMed ID: 21989542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.
    Griffiths CE; Sterry W; Brock F; Dilleen M; Stefanidis D; Germain JM; Mallbris L
    Br J Dermatol; 2015 Jan; 172(1):230-8. PubMed ID: 24861696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.